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Abbreviations 
 
adm: Administer, administered, administration, etc. 
BIC: Bayesian Information Criteria 
BSA: Body Surface Area 
CT: Combination Therapy 
DNA: Deoxyribonucleic acid 
Gap: Short for the administration gap between (first) bevacizumab and (second) 
pemetrexed/cisplatin 
IP: Intraperitoneal 
IIV: Inter-individual variability 
IV: Intravenous 
NSCLC: Non-Small Cell Lung Carcinoma 
PD: Pharmacodynamic 
PK/PD: Pharmacokinetic/pharmacodynamic 
PEM/CIS: Pemetrexed/cisplatin 
BEV-PEM/CIS: Pemetrexed/cisplatin-bevacizumab 
PK: Pharmacokinetics 
ROS: Reactive Oxygen Species 
RFU: Relative Fluorescence Units 
sGOF: Standard Goodness-Of-Fit 
VPC: Visual Predictive Check 
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Abstract 1 
Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-2 
squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity 3 
by inducing transient tumor vasculature normalization. BEV-PEM/CIS has a narrow therapeutic 4 
window. Therefore, it is an attractive target for administration schedule optimization. The 5 
present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in 6 
NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. 7 
We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in 8 
humans. Our simulations suggest that the efficacy loss in scheduling BEV-PEM/CIS at too great 9 
of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap.  10 
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Introduction 11 
Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) combination therapy has been shown to be 12 
an effective first line and maintenance therapy for non-small cell lung cancer (NSCLC) in Phase 13 
II and Phase III clinical trials(1–3). Pemetrexed inhibits enzymes necessary for pyrimidine and 14 
purine synthesis – primarily thymidylate synthase, which is necessary for thymidine synthesis 15 
and tumor cell replication(4). Cisplatin is an alkylating agent which crosslinks adjacent N7 16 
centers on purine residues, damaging DNA, disrupting repair, and disrupting purine 17 
synthesis(5–7). Disrupting DNA substrate supply results in S-phase arrest, DNA repair 18 
disruption, and eventually apoptosis(8,9). Cisplatin also significantly disrupts calcium and 19 
reactive oxygen species (ROS) regulation, inducing cellular lesions which further sensitizes 20 
cancer cells to apoptosis(7).  21 
 22 
In contrast to the effect of PEM/CIS, i.e. DNA damage, bevacizumab is an anti-VEGF (vascular 23 
endothelial growth factor) humanized monoclonal antibody. VEGF is an angiogenic potentiator 24 
which promotes the growth of endothelial tissue necessary for arteries, veins, and lymphatics. 25 
By limiting neovascular growth, and therefore blood delivery to neoplasms, bevacizumab 26 
exhibits limited antiproliferative properties(10). 27 
 28 
More importantly, bevacizumab transiently induces a pruning effect on neovascular beds, which 29 
normalizes blood supply to neovascularly dense tissues (i.e. tumors)(11–13). By normalizing 30 
blood supply, bevacizumab enhances chemotherapeutic (i.e. PEM/CIS) delivery to 31 
neoplasms(14,15). 32 
 33 
The effects of BEV-PEM/CIS are generalized i.e. any cell capable of uptaking the drugs are 34 
susceptible to their effects, especially rapidly-dividing cells such as myeloid cells(16).  35 
Accordingly, BEV-PEM/CIS has a narrow therapeutic window and generalized side-effects(3). 36 
Previous studies on BEV-PEM/CIS suggest that sequential administration of BEV-PEM/CIS (i.e. 37 
BEV before PEM/CIS) outperforms concomitant scheduling of BEV-PEM/CIS in treating 38 
NSCLC(12,17–19). This makes BEV-PEM/CIS an attractive target for scheduling optimization 39 
via modeling and simulation, as a range of practical predictions – such as optimal scheduling in 40 
humans – can be made without the considerable time and resource investment required to 41 
conduct in vivo experiments. These predictions can be used to guide future studies, greatly 42 
accelerating drug development(20).  43 
 44 
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 45 
In our previous work on BEV-PEM/CIS published in Imbs et al. 2017(17), mice with NSCLC 46 
tumor xenografts were administered bevacizumab with PEM/CIS combination therapy (CT) in 47 
either concomitant, or delayed (i.e. bevacizumab before PEM/CIS) scheduling. The NSCLC 48 
tumors had been modified such that tumor growth could be tracked over time via either 49 
bioluminescence or fluorescence. Following previous theoretical investigations, the dataset 50 
generated from the mice with bioluminescent tumors was used to develop a semi-mechanistic 51 
PK/PD model for tumor dynamics in response to BEV-PEM/CIS(21,22). The model was then 52 
used to predict the optimal scheduling gap between bevacizumab and PEM/CIS administration.  53 
 54 
The aim of this follow-up modeling work was to both refine and expand upon previous results on 55 
BEV-PEM/CIS CT using the much larger fluorescence dataset generated in Imbs et al. 56 
2017(17). We first showed that the semi-mechanistic model previously developed better 57 
explained the data than comparable models (i.e. we validated the previously developed 58 
structural model). Then, we refined the parameter estimates of the model, and used it to predict 59 
the optimal scheduling gap between bevacizumab and PEM/CIS administration. Next, we used 60 
stochastic simulations to explore the marginal loss in therapeutic efficacy when BEV-PEM/CIS 61 
was administered at a sub-optimal gap, the effect of bevacizumab dose scaling on population 62 
optimal gap, as well as the inter-individual variability (IIV) of optimal gap. Lastly, using literature 63 
human PK/PD models and parameter estimates, we were able to scale the model to estimate 64 
the optimal scheduling of BEV-PEM/CIS in humans. 65 
 66 
Methods 67 
Experimental Procedure 68 
Comprehensive details on animals and the experimental procedure are available in Imbs et 69 
al. 2017(17). Briefly, on Day 0 of the experiment, tumors (ca 120,000 cells) consisting of H460 70 
human NSCLC transfected with luciferase and the tdTomato gene (H460 Luc+ tdTomato+, 71 
Perkin Elmer France) were injected ectopically into the left flank of 90 mice. Animals were 72 
pathogen-free, immunocompromised, 6-week-old, female Swiss nude mice (Charles River, 73 
France). The mice were randomized into one of five treatment groups. The first study group 74 
(Control) received no treatment. The second treatment group (PEM/CIS) was administered both 75 
100 mg/kg of pemetrexed IP and 3 mg/kg of cisplatin IP on Days 14, 28, and 42 of the 76 
experiment. The third, fourth, and fifth treatment groups (BEV-PEM/CIS) received the same 77 
PEM/CIS treatment as the second experimental group.  78 
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 79 
In addition, the BEV-PEM/CIS treatment groups were administered 20 mg/kg IP of bevacizumab 80 
either concomitantly with the PEM/CIS administrations (Group 3), 3 days prior to each PEM/CIS 81 
administration (Group 4), or 8 days prior to each PEM/CIS administration (Group 5) – see Table 82 
S1 for administration tabulation.  83 
 84 
Tumor growth was monitored on a minimum bi-weekly basis using Ivis Spectrum imager (Perkin 85 
Elmer France) and images were acquired and analyzed using the Living Image 6.0. software 86 
(Perkin Elmer France). 87 
 88 
Mice were supplied with paracetamol supplemented water (e.g. 80 mg/kg/day) to prevent 89 
disease-related pain. Animals showing signs of distress, pain, cachexia (i.e. loss of 10% of body 90 
mass), or extensive tumor proliferation (i.e. within 2-3 cm) were euthanized. All animals were 91 
euthanized on Day 87 of the experiment. All experiments were approved by the local ethical 92 
committee at French Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la 93 
Recherche, and registered as #2015110616255292. 94 
 95 
PK/PD Structural Model Building and Evaluation 96 
The PK models for bevacizumab, pemetrexed, and cisplatin were derived from previously 97 
published PK models in mice(23–25). The parameters for these models were fixed to the typical 98 
values from those studies and assumed no IIV. 99 
 100 
The PD model was selected from a series of sequentially fit tumor growth and drug effect 101 
models. First – using only the control dataset – the exponential, linear-exponential, and 102 
Gompertz growth model were cross-evaluated as models of unperturbed tumor growth(26). 103 
Then, incorporating the full dataset into the fit, the log-kill effect of bevacizumab, log-kill effect of 104 
pemetrexed, and log-kill effect of cisplatin were each considered. The interaction effect between 105 
bevacizumab and PEM/CIS was included to represent the synergistic effect of bevacizumab. 106 
Following previous work for the effect of cytotoxic drugs, three cellular death compartments 107 
were included in the PD portion of the model to represent the delay between cellular damage 108 
due to PEM/CIS and cell death(27). 109 
 110 
Competing models were evaluated numerically using Bayesian information criteria (BIC) and the 111 
precision of parameter estimates – defined as the relative standard error of the estimate (RSE). 112 
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Observed vs. predicted plots, individual fit plots, and Visual Predictive Checks (VPCs) were 113 
produced to graphically assist model evaluation (as automated in Monolix 2018R2). VPCs were 114 
produced using the default estimation process for VPCs as of Monolix 2018R2 i.e. to create the 115 
90% prediction intervals for the 10th, 50th, and 90th percentiles, 500 simulations are performed 116 
using random individual parameters and the design structure of the experiment. 117 
 118 
After model selection, the statistical correlations between random-effects were explored via 119 
visual inspection. Correlations plots between random effects were produced, defined as 𝜂𝑖,𝑡,𝜙1 120 
vs 𝜂𝑖,𝑡,𝜙2  i.e. the random effect 𝜂, of individual 𝑖, at time 𝑡, of parameter 1, i.e. 𝜙1, vs the random 121 
effect 𝜂, of individual 𝑖, at time 𝑡, of parameter 2, i.e. 𝜙2. The full posterior distribution of the 122 
parameters were used in place of EBEs to avoid visual artifacts due to shrinkage as suggested 123 
by Lavielle, et al, 2016(28) and Pelligand L, et al, 2016(29). Statistical correlations between 124 
random effects were also numerically assessed using a Pearson correlation test at a P < .05 125 
threshold. 126 
 127 
SAEM convergence and final model parameterization were graphically assessed by inspection 128 
of search stability, distribution of the individual parameters, distribution of the random effects, 129 
individual prediction vs. observation, individual fits, distributions of the weighted residuals, as 130 
well as VPCs. 131 
 132 
The precision of parameter estimates was numerically assessed using RSE. The normality of 133 
random effects distributions, the normality of individual parameter distributions, and the 134 
normality of the distribution of residuals were each numerically assessed using a Shapiro-Wilk 135 
test (P < .05). The centering of the distribution of residuals (i.e. centered on 0) was numerically 136 
assessed using a Van Der Waerden test (P < .05). 137 
 138 
Parameter stability was assessed by comparing parameterizations resulting from random-initial 139 
starting value selection – as implemented in the Monolix assessment suite. The assessment 140 
suite performs 5 SAEM parameterizations in series using random initial parameter values 141 
uniformly drawn from the interval from approximately 60% to 160% of final parameter estimates. 142 
The SAEM of the individual parameterizations was then tracked between runs - giving a range 143 
of parameter value estimates, RSEs, and log-likelihoods to compare. This assessment was 144 
used to ensure that the algorithm did not converge to a log-likelihood local minimum during the 145 
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process of producing final parameter estimates. The settings described are the default as of 146 
Monolix 2018R2. 147 
 148 
Simulations 149 
Simulations were performed in R 3.4.4 using Simulx 3.3.0(30) to simulate from Monolix run 150 
files. First, a function was built which accepted treatment schedule, parameter substitutions, 151 
dose, and number of individuals as input and produced a simulated population as an output. 152 
This function was simply a convenience wrapper of Simulx for automation purposes and was 153 
verified by reproducing VPCs per treatment group. Simulation set 1 was used to predict the 154 
optimal gap between administration of bevacizumab and PEM/CIS. Simulation set 2 produced 155 
an estimate of the IIV of the optimal gap. Simulation set 3 examined the anticipated effect of 156 
varying the dose of bevacizumab on the optimal gap. Simulation set 4 scaled predictions of 157 
BEV-PEM/CIS efficacy to humans. All simulations were of population level response (i.e. 158 
simulated without RSE or IIV) except for simulation set 2 (simulated without RSE and with IIV) 159 
which used 1000 monte carlo samples. Further details are provided in the supplementary 160 
methods. 161 
 162 
Quality assessment 163 
All mlxtran and R codes were assessed for quality control by an independent evaluator. 164 
 165 
Results 166 
Error Model 167 
Measurement error was best described using a log-normal constant-error model (equation 168 
1). The natural-log of each individual measurement, 𝑙𝑛(𝑦𝑖𝑗) with individual i and repetition j, was 169 
modeled as a measurement centered on the natural-log mean of 𝑦𝑖𝑗  over j, i.e. 𝑙𝑛(𝑥̄ 𝑖), in addition 170 
to some residual error, 𝜖𝑖𝑗, normally distributed, centered on zero, and with standard deviation 171 
𝑎. 172 
𝑦𝑖𝑗  =  𝑥̄ 𝑖 ⋅ 𝑒
𝜖𝑖𝑗    𝑤ℎ𝑒𝑟𝑒   𝑙𝑛(𝑦𝑖𝑗)  =  𝑙𝑛(𝑥̄ 𝑖) + 𝜖𝑖𝑗    |   𝜖 ∼ 𝑁(0, 𝑎)   (Equation 1) 173 
 174 
The sGOF graphics and numerical analyses supported that a log-constant error model best fit 175 
the data. The log-constant error model was not rejected for both the Kolmogorov-Smirnov test 176 
for normality (P = .22) nor the Pearson chi-square normality test (P = .0509). In contrast, a 177 
constant error model was rejected by these two tests (see Figure S1 for further details). 178 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/540849doi: bioRxiv preprint first posted online Feb. 5, 2019; 
7 
 
 179 
PK/PD Structural Model Building 180 
No outliers were identified during initial data exploration. Therefore, no collected data were 181 
excluded from model building.  182 
 183 
The pharmacokinetics of bevacizumab, pemetrexed, and cisplatin were each modeled using 184 
one-compartment models with first order IP absorption and first order elimination based on 185 
literature descriptions and PK parameter estimates(23–25). Random effects (i.e. 𝜂𝑝𝑘) were set 186 
to 0 as individual PK was not reported in these experiments. 187 
 188 
A Gompertz function (Equation 2) was found to best describe the unperturbed tumor growth 189 
𝑉(𝑡), based on its fit performance over competing models, low RSE on parameter estimates, 190 
and literature-established descriptive quality. 191 
(α − β ∙ ln(𝑉 𝑉𝑐⁄ )) ∙ 𝑉         (Equation 2) 192 
 193 
Due to sparseness in sampling, more complex semi-mechanistic models of growth were not 194 
supported by the data. Parameters 𝛼 and 𝛽 represent the proliferation rate of the tumor cells 195 
and rate of exponential decrease of the tumor relative growth rate, respectively. 𝑉𝐶 is the unit 196 
value of relative fluorescence units (RFU) corresponding to one cell, i.e. the proportionality 197 
constant between RFU and the number of cancer cells in the fluorescent volume. 198 
 199 
𝑉𝐶 was estimated externally from Monolix by conducting a naive-pooled, linear-regression on 200 
the natural-log of the full dataset. The regression gave a rough estimate of 𝑉0 which was then 201 
scaled by the approximate number of cells injected at time 0 (ca. 120,000 cells) to derive 𝑉𝐶 =202 
5.064 × 10−4 RFU. 203 
 204 
After selecting an appropriate growth model, the log-kill effects of pemetrexed, cisplatin, and 205 
bevacizumab were each considered in parallel. The log-kill effect of bevacizumab was 206 
estimated as insignificant and removed from the model. The estimation of the log-kill effect of 207 
pemetrexed and cisplatin were found to be highly correlated. To reduce model complexity, only 208 
their combined concentration, 𝐶(𝑡), and a corresponding log-kill parameter, 𝛾, were considered 209 
in the final model (Equation 3). 210 
 211 
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[
 
 
 
 
 
 
 
 
 
𝜏
𝑄(𝑡)
V̇
𝑍1̇
𝑍2̇
𝑍3̇
𝑁 ]
 
 
 
 
 
 
 
 
 
=
[
 
 
 
 
 
 
 
 
 
𝜏𝑏𝑜𝑢𝑛𝑑  ∙  10
1 + 𝛿 ∙ 𝐴(𝑡 − 𝜏)
(α − β ∙ ln(𝑉 𝑉𝑐⁄ )) ∙ 𝑉 − γ𝑄𝐶𝑉
𝛾𝑄𝐶𝑉 − 𝑘 ∙ 𝑍1
𝑘 ∙ (𝑍1 − 𝑍2)
𝑘 ∙ (𝑍2 − 𝑍3)
𝑉 + 𝑍1 + 𝑍2 + 𝑍3 ]
 
 
 
 
 
 
 
 
 
 ,
[
 
 
 
 
 
 
 
 
 
-
-
𝑉(0) = 𝑉0
𝑍1(0) = 0
𝑍2(0) = 0
𝑍3(0) = 0
- ]
 
 
 
 
 
 
 
 
 
     (Equation 3) 212 
 213 
𝐴(𝑡) represents the plasma concentration of bevacizumab. 𝑄(𝑡) represents the synergistic effect 214 
of improved vascular quality. In brief, the increase in neoplasm vascular quality due to 215 
bevacizumab typically occurs within a period of a few days after administration. To represent 216 
this delay in effect, time (𝑡) was delayed by 𝜏. Parameter 𝛿 represents the proportional increase 217 
in PEM/CIS efficacy due to vascular quality improvement under bevacizumab therapy. 218 
 219 
The estimation of 𝜏 was bounded between 0 and 10 using the link function 𝜏 = 𝜏𝑏𝑜𝑢𝑛𝑑 ⋅ 10, 220 
where 𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑) ∼ 𝑁(0,1). All other parameters were best estimated as log-normally 221 
distributed. The full statistical representation of individual parameters, 𝜙𝑖, estimated via SAEM is 222 
shown in Equation 4, where the full structural model is denoted by 𝐹. 223 
 224 
(Equation 4) 225 
𝑦𝑖𝑗 =  𝐹(𝛷𝑖 , 𝑡𝑖𝑗) ∙ 𝑒
𝑎 𝜀𝑖𝑗 , 𝑗  𝜖  {1,… , 𝑛𝑖} 226 
 227 
𝜙𝑖        =        
[
 
 
 
 
 
 
 
 
 
 
𝛼𝑖  =  𝛼𝑝𝑜𝑝 ∙  𝑒
𝜂𝛼,𝑖
𝛽𝑖  =  𝛽𝑝𝑜𝑝 ∙  𝑒
𝜂𝛽,𝑖
𝛾𝑖  =  𝛾𝑝𝑜𝑝  ∙  𝑒
𝜂𝛾,𝑖
𝛿𝑖 = 𝛿𝑝𝑜𝑝 ∙  𝑒
𝜂𝛿,𝑖
𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑𝑖)  =  𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑𝑝𝑜𝑝) + 𝜂𝜏𝑏𝑜𝑢𝑛𝑑,𝑖
𝑉0𝑖 = 𝑉0𝑝𝑜𝑝 ∙  𝑒
𝜂𝑉0,𝑖
𝑘𝑖 = 𝑘𝑝𝑜𝑝 ]
 
 
 
 
 
 
 
 
 
,        𝑖 𝜖 {1, … ,𝑁} 228 
 229 
Cellular death due to chemotherapeutic treatment was modeled as a three-compartment 230 
transition from the growth compartment to death(27). The compartments are labeled 𝑍1, 𝑍2, and 231 
𝑍3 (numbering respective to their order) and transition between compartments is governed by 232 
intercompartmental clearance parameter 𝑘. 233 
 234 
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𝑘 was not identifiable using the SAEM algorithm. Thus, after a period of manual exploration, 𝑘 235 
was set to the value of 0.3. This choice is consistent with the parameterization made in Imbs et 236 
al(17). This choice also limits the total transition time from the tumor mass compartment to 237 
cellular death to the order of a day which is consistent with upper limits of cellular death 238 
clearance(31). 239 
 240 
The full tumor size, 𝑁, was the sum of the size of unperturbed cells, 𝑉, as well as the size of 241 
damaged cells undergoing cellular death i.e. 𝑍1 + 𝑍2 + 𝑍3. 242 
 243 
No correlations between random effects were statistically significant enough to be included in 244 
the final model (Figure S2). Full parameter estimates and model diagram are provided in Table 245 
1 and Figure 1 respectively. Model diagnostics are collected in Figure 2 through Figure 4. 246 
 247 
Simulations 248 
Simulating the experimental treatments with a range of administration gaps from 0 to 10 249 
days (step-size = 0.1 day) suggested that the optimal time delay between scheduling 250 
bevacizumab and PEM/CIS in mice is 2.0 days (Simulation set 1).  251 
 252 
The simulated IIV of the optimal gap was relatively small. Only three values of individual optimal 253 
gap were produced. 96.5% of the virtual animals had an individual optimal gap of 2.0 days, 254 
1.0% of the virtual animals had an individual optimal gap of 2.1 days, and 2.5% of virtual 255 
animals had an individual gap of 1.9 days (Simulation set 2). 256 
 257 
Scaling the dosage of bevacizumab to either 30 mg/kg or 10 mg/kg produced no effect in the 258 
estimated optimal gap and produced no effect in the IIV of the optimal gap (Simulation set 3). 259 
 260 
Simulations of the typical human response to chemotherapy and bevacizumab were performed 261 
using IV administration, two-compartment absorption, and first order elimination models and 262 
parameters(32–34). Dosage and frequency of administration recommendations for BEV-263 
PEM/CIS were adapted from DailyMed, a product label database maintained by the U.S. 264 
National Library of Medicine(35). Average adult weight and BSA were obtained from Center for 265 
Disease Control and literature estimates respectively(36,37). 266 
 267 
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Except for the proliferation rate of the tumor cells and rate of exponential decrease of the tumor 268 
relative growth rate (i.e. 𝛼 and 𝛽), the PD model and parameterization were reused exactly as 269 
they were determined in the mouse portion of the model. 𝛼 and 𝛽 estimates were obtained from 270 
Bilous et al. 2018(38), where clinical NSCLC doubling times reported in Friberg and Mattson, 271 
1998(39) were used to estimate population 𝛼 and 𝛽 for NSCLC in humans. The value of VC 272 
came from the classical assumption that a 1 mm3 volume of tumor cells is approximately 106 273 
cells(40). V0 was arbitrarily set to 3 cm3. 274 
 275 
The full PK/PD model was then used to simulate the typical cancer growth under various 276 
administration schedules with a starting tumor volume of 3 cm3. Parameter estimates are 277 
reported in Table 2 and simulation summaries are depicted in Figure 5. The estimated optimal 278 
gap between bevacizumab and PEM/CIS administration in humans was 1.2 days. 279 
 280 
Discussion 281 
By normalizing tumor vasculature, bevacizumab improves delivery of PEM/CIS to tumors which 282 
increases PEM/CIS anti-tumor efficacy. Pemetrexed and cisplatin each have a narrow 283 
therapeutic window, low clearance, and high toxicity. It is therefore critical that BEV-PEM/CIS 284 
doses are administered as efficiently as possible. This makes BEV-PEM/CIS a natural fit for 285 
modeling and simulation studies, as the drug scheduling can be optimized without the need for 286 
multiple time and resource intensive in vivo studies. In this analysis we conducted an in silico 287 
study of the optimal administration of BEV-PEM/CIS in a xenograft, and human, model of 288 
NSCLC by constructing a mathematical model of tumor dynamics in response to BEV-PEM/CIS. 289 
In constructing that model, we were able to validate and refine previous modeling in BEV-290 
PEM/CIS. Greater precision in parameter estimates was achieved through external estimation 291 
of 𝑉𝑐, external validation of the residual error model, as well as using the larger fluorescence 292 
dataset to obtain final parameter estimates. Then, after exploring a range of predictions in mice, 293 
we scaled our model to predict optimal scheduling in humans. 294 
 295 
The molecular profile of xenografts has a high degree of similarity with the molecular profile of 296 
the primary tumors from which the xenograft was derived(41) This indicates that there is 297 
compositional heterogeneity between xenografts and primary tumors. In addition, human 298 
NSCLC H460 cells are an experimentally established paradigm for modeling NSCLC 299 
tumors(42–44). Xenografts were grown after subcutaneous implantation in the mice flank, and 300 
not directly in the lungs. This is because monitoring tumor growth of lung orthotopic xenografts 301 
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with non-invasive techniques is limitingly difficult due to both the rapid movements of the chest 302 
in mice during imaging, and photon emission attenuation by the high amount of water in lung 303 
tissues.  Consequently, ectopic xenografts were considered as the more robust experimental 304 
model for data collection. Taken together, these considerations motivated our choice of 305 
experimental model and are the basis for which we scaled our mathematical model for making 306 
predictions in humans.  307 
 308 
In the error modeling portion of the experiment, we demonstrated a strategy through which the 309 
choice of the error model can be validated externally to the primary dataset by including 310 
supplementary data collection in the experimental design. This simplified the error modeling 311 
step in the model building process. 312 
 313 
The next stage of this study consisted of determining whether the semi-mechanistic model of 314 
tumor dynamics in response to BEV-PEM/CIS developed in Imbs et al. 2017(17) best fit the unfit 315 
fluorescence data from the same study. During model building, we attempted to balance our 316 
model building procedure between model performance (empirical fit) and the underlying biology, 317 
an approach often referred to as the middle-out approach(45,46). 318 
 319 
In selecting potential PD models of tumor growth, several semi-mechanistic models were fit to 320 
the experimental data. The Gompertz model and linear-exponential model performed 321 
comparably. The parameters of the Gompertz model were estimated with greater precision than 322 
the parameters of the linear-exponential model (RSE) where the linear-exponential model was 323 
fit with a lower BIC than the Gompertz model. Ultimately, the Gompertz model was chosen over 324 
the linear exponential model due to the physiological relevance of its construction. 325 
 326 
The parameterization of the final model was slightly unstable due to modest 327 
overparameterization. To compensate for this, 𝑘 was fixed to a reasonable physiological 328 
estimate to improve precision of parameter estimates, and the search for 𝜏 was upper bounded 329 
to reduce spurious individual parameter estimates. In addition, the direct anti-proliferative effect 330 
of bevacizumab, and individual effects of pemetrexed and cisplatin, respectively, were removed 331 
from the model. 332 
 333 
The modeling phase of the study resulted in several validations of previous findings. First, we 334 
confirmed the validity of the mathematical model previously published in Imbs et al. 2017(17), 335 
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which we fit to our dataset. In doing so, we reconfirmed the ability of the model to describe BEV-336 
PEM/CIS scheduling. We also reconfirmed the efficacy improvement of BEV-PEM/CIS dosing 337 
over PEM/CIS or control. We observed that a 3 day gap in scheduling is superior to both 338 
concomitant scheduling and an 8 day gap in scheduling. We were also able to build on previous 339 
work by identifying with greater precision the parameters underlying the mathematical model of 340 
BEV-PEM/CIS in NSCLC-tumor bearing mice. 341 
 342 
In our mouse simulations, the final tumor volume (after 67 days) in the optimal scheduling group 343 
with BEV-PEM/CIS (gap = 2.0 days) was 88.5% of the size of final tumor volume in the 344 
concomitant scheduling group. This is consistent with our experimental results i.e. that mice 345 
administered bevacizumab approximately 2 days before PEM/CIS have a moderately better 346 
response (i.e. greater tumor size reduction) to BEV-PEM/CIS than mice who are administered 347 
BEV-PEM/CIS concomitantly. 348 
 349 
The small magnitude of improvement in 2.0 day gap over concomitant scheduling is likely due to 350 
sub-optimal dosage and frequency of administration of BEV-PEM/CIS in the mice. We 351 
observed, by exploration, that a more robust preclinical response might be achieved by doubling 352 
the frequency of doses in mice and increasing the individual dosages by 50%. 353 
 354 
We also found, through simulation, that scaling the dose of bevacizumab had no effect on the 355 
optimal gap and that IIV on gap is low. 356 
 357 
Predictions made by our model agree with previous findings in BEV-PEM/CIS scheduling. The 358 
order of the optimal scheduling delay (2.0 days) is within the 1 to 5 day gap predictions of 359 
previous studies(12,18,19). Studies in tumor perfusion and bevacizumab showed Day 1 and 360 
Day 4 decrease in tumor perfusion which is consistent with the marginal predictions in our study 361 
i.e. optimal perfusion should be on the order of 2 days with comparable marginal losses on 362 
either side of that minimum(47). 363 
 364 
After exploring various predictions in mice made by the model, the PK portion of the model was 365 
re-parameterized and the parameters of the PD portion of the model were scaled to simulate the 366 
relationship between varied administration schedules (i.e. gap) and efficacy in humans. Using 367 
this adapted parameterization, we estimated both optimal schedule of administration of BEV-368 
PEM/CIS in humans and the marginal effects of a sub-optimal administration schedule of BEV-369 
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PEM/CIS in humans (i.e. bevacizumab administered too many or too few days before 370 
PEM/CIS). 371 
 372 
In our human simulations, we predicted a robust improvement in response to sequential BEV-373 
PEM/CIS relative to concomitant scheduling. The final tumor volume (after 67 days) in the 374 
optimal scheduling group (gap = 1.2 days) was 30% of the size of the final tumor volume in the 375 
concomitant scheduling group. If these predictions are accurate, scheduling optimization could 376 
result in significant improvement in BEV-PEM/CIS CT efficacy with no increase in toxicity. 377 
 378 
The predicted scale of the increase in efficacy after scheduling optimization was much greater in 379 
the human simulations than was either predicted by the mouse simulations, or was measured 380 
empirically in mice. This is at least partially due to the greater study that has been undertaken in 381 
optimizing dosages for human treatment of NSCLC. However, these promising estimates should 382 
not be substituted for clinical testing. 383 
 384 
When exploring marginal efficacy loss in sub-optimal administration schedules, we consistently 385 
found that the marginal cost of scheduling bevacizumab and PEM/CIS too close together in time 386 
was greater than the marginal cost of scheduling bevacizumab and PEM/CIS with too great of a 387 
gap in administration - in both mice and humans. This indicates that any potential clinical 388 
studies in antiangiogenics and cytotoxics should weight scheduling recommendations toward 389 
scheduling at slightly too large of gap. 390 
 391 
Finally, the tumor microenvironment is known to be complex and varied. Tumor tissues contain 392 
necrotic pockets, heterogenous and dynamic microvasculature, and various sub-mutations 393 
which result in differential local growth rate and drug sensitivity. Considering this biological 394 
heterogeneity would greatly improve future model predictions and scalability between species.   395 
 396 
In summary, our analysis confirms previous findings in BEV-PEM/CIS scheduling while 397 
improving precision of parameter estimates, improving prediction quality and detail, and scaling 398 
the model to predict the optimal scheduling of BEV-PEM/CIS in humans.  399 
 400 
Antiangiogenics will continue to be useful agents in oncology. There are currently several other 401 
antiangiogenics regularly used in combination with cytotoxics which could potentially benefit 402 
from sequential administration (i.e. antiangiogenic then cytotoxic)(48). Of note, bevacizumab is 403 
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currently only approved for concomitant administration with chemotherapy in all of its indications 404 
e.g. lung cancer, breast cancer, gastric cancer, etc. This contrasts with the optimized sequential 405 
scheduling that model simulations suggest.  406 
 407 
There is a recent trend to develop model-informed drug development to optimize anticancer 408 
therapy. Our work highlights how mathematical modeling could help to refine clinical treatment 409 
modalities. The semi-mechanistic nature of this model allows it to be modularly reconfigured to 410 
extend predictions to other antiangiogenics as well as novel therapeutic paradigms such as the 411 
immune checkpoint inhibitor, monoclonal antibody pembrolizumab(49). This work continues to 412 
lay the foundation for building systems pharmacology models of the effect of antiangiogenic  413 
and antiproliferative combination therapy in advanced NSCLC. Tortuous vasculature is a 414 
phenotype exhibited by many solid tumors, and predicting optimal antiangiogenic scheduling 415 
could greatly increase the efficacy of future oncology therapeutics and combination 416 
therapies(50). 417 
  418 
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Table 1 Pharmacodynamic Model Parameters for Tumor Proliferation in NSCLC-Xenografted Mice
Model parameter estimates (fixed and random-effects) as well as standard errors as determined by the 
Stochastic Approximation Expectation-Maximization algorithm as implemented in Monolix 2018R2.
Table 1 
Model Parameter Estimate SE RSE (%) IIV IIV (CV%) 
𝜶 0.77 day
-1
 0.0081 1.06 0.037 4.76 
𝜷 0.04 day
-1
 0.0005 1.16 0.015 33.55 
𝜸 35.74  (mg·day)
-1
 6.36 17.79 0.46 1.28 
𝜹 3.73  (mg·day)
-1
 0.92 24.70 0.35 9.51 
𝝉
bound
 .119 days 0.0017 1.50 0.017 14.50 
𝑽0 3.4 RFU* 0.27 22.55 1.73 143.03 
𝒌 0.30 days - - - - 
Residual Error Variance 0.43 0.01 2.55 - - 
   *RFU: Relative Fluorescence Unit 
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Table 2 Model Parameterization for Simulations of NSCLC treated with BEV-PEM/CIS in Humans
Except for the proliferation rate of the tumor cells and rate of exponential decrease of the tumor relative 
growth rate (i.e. 𝛼, 𝛽), the PD model and parameterization were reused exactly as they were determined in 
the mouse portion of the model. 𝛼 and 𝛽 estimates were obtained from Bilous et al. 2018(38), where 
clinical NSCLC doubling times reported in Friberg and Mattson, 1998(39) were used to estimate 
population 𝛼 and 𝛽 for NSCLC in humans. The value of 𝑉𝑐 came from the classical assumption that a 1 
mm3 volume of tumor cells is approximately 106 cells(40). 𝑉0 was arbitrarily set to 3 cm
3. 𝑉, 𝑘𝑚,𝑛, and 𝑄
represent volume, compartmental clearance from compartment m to compartment n, and 
intercompartmental clearance respectively. 
Table 2    
Pemetrexed Pharmacokinetics   Pharmacodynamics 
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𝑉1 12.9 L   𝛽 1.03E-3 day
-1
 
𝑄 14.4 mL/min   𝛾 35.7 (mg·day)
-1
 
𝑉2 3.38 L   𝛿 3.73 (mg·day)
-1
 
Cisplatin Pharmacokinetics   𝜏 1.19 days 
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𝑉1 22.7 L   𝑘 0.3 days 
𝑄 10.7 L/h   𝑉𝑐 10E-3 mm
3
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Bevacizumab Pharmacokinetics     
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𝑉1 2.8 L     
𝑘12 0.22 day
-1
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Figure 1 Structural Model Diagram
The scheme of the structural model is 
depicted to the right. Unperturbed cells grow 
at rate governed by 𝛼 and 𝛽. When a 
cytotoxic is introduced into the system, the 
cytotoxic impairs the growth of the tumor by 
sending cells into a death succession. The 
parameter which determines the cytotoxic 
efficacy, 𝛾, is scaled by both the 
concentration of cytotoxics, 𝐶(𝑡), and the 
volume of the tumor, 𝑉(𝑡).  Bevacizumab 
improves vascular quality, 𝑄(𝑡), after time 
delay, 𝜏, which scales the cytotoxic effect by 
parameter 𝛿. When a cell is damaged by 
cytotoxics it begins a progression from 
unperturbed growth – compartment 𝑉(𝑡) – to 
damage compartments 𝑍1 through 𝑍1. 
Eventually the cell exits the tumor volume as 
it dies. The rate of transfer between damage 
compartments is governed by 
intercompartmental clearance parameter 𝑘.
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Figure 2 Standard Goodness-of-Fit Diagnostic Plots
On the left is individual predictions vs. observations and on the right are the individualized weighted 
residuals (IWRES) vs time. During model fitting, observations were natural-log-transformed to stabilize 
predictions. Therefore, residuals, predictions, and observations are natural-log-transformed in these 
figures. The predictions are approximately normally distributed. On the left, the one-to-one prediction line 
is the center solid black line, the spline (average agreement between individual prediction and 
observation) is solid orange, the dashed black lines are the borders of the 90% prediction interval. On the 
right, the zero residual error line is the center dashed black line, the spline is solid orange. The dashed 
black lines are the borders of the 90% prediction interval.
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Figure 3 Sample of Individual Fits
The blue dots represent individual observations while the solid violet line represents individual fits.
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Figure 4 Combined and Stratified Visual Predictive Checks 
The blue lines are the 10th, 50th, and 90th empirical percentiles calculated for each unique value of time. 
Blue and pink areas represent 90% prediction intervals for the 10th (blue), 50th (pink), and 90th (blue) 
percentiles. Prediction intervals are calculated by Monte Carlo simulation. To create prediction intervals for 
each unique value of time, 500 simulations are performed using random individual parameters. The red 
areas and red-circled points represent areas where empirical measurements fall outside of the bounds of 
the 90% prediction intervals.
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Figure 5 Human Pharmacodynamic and 
Pharmacodynamic Simulations Summary
To produce these figures, bevacizumab 
(BEV) was administered anywhere from 0 
to 10 days (in steps of 0.1) before 
pemetrexed/cisplatin (PEM/CIS) was 
administered. Tumor growth was 
simulated from 0 to 67 days with no IIV 
and no RSE. In the top figure, AUC of 
tumor growth vs gap (0 to 10 days) is 
depicted. In the middle figure, tumor 
dynamics over time, with gap indicated by 
color, are depicted. In the bottom panel, 
the PK of BEV-PEM/CIS is depicted with 
gap indicated by color. The top figure 
indicates that the optimal scheduling gap 
is 1.2 days and the middle figure depicts 
the difference in tumor volume between 
administration gaps. The patient with 
optimal scheduling had a final tumor 
volume approx. 30% the size of the 
concomitant scheduling.
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